Class I phosphoinositide 3-kinases (PI3Ks) are now known to regulate cell growth, cell metabolism, cell survival, cell cycle entry and cell movement. Insulin utilizes Class Ia PI3Ks for regulation of glucose homeostasis and impairment in this regulation can result in Type II diabetes. Activating mutations in Class Ia PI3Ks or inactivating mutations in PTEN, a phosphatase that degrades PI3K products, are some of the most frequent events in human cancers and the majority of solid tumors have mutations in some component of the PI3K signaling pathway. PI3K inhibitors are now in clinical trials for treating cancers and for immune suppression and there is optimism about potential benefits, but concern about potential adverse affects. Over the past granting period we have attempted to understand the complex network of PI3K activation and downstream signaling using a combination of biochemical approaches, cell-based studies and mouse genome manipulations. While work from our laboratory and many other laboratories has resulted in considerable progress in understanding this complex signaling network over the past five years, it is clear that there is much to be done. Our goals for the next granting period are focused on uncovering the complexity of Class Ia PI3K regulation and downstream signaling. We will investigate the relative roles of PI-3,4-P2 and PI-3,4,5-P3 in cellular regulation. We have recently found that a phosphatases that degrades PI-3,4-P2 is a tumor suppressor in human solid tumors suggesting that this lipid plays an important role in cell transformation. We will also determine the mechanism by which the p85 regulatory subunit controls Class Ia PI3K signaling. In particular, we will investigate the importance of post-translational modifications we have recently identified on p85alpha. Finally, we will investigate stochastic regulation of the PI3K pathway in epithelial cells.

Public Health Relevance

The PI3K pathway is the most frequently mutated pathway in human cancers. This grant has funded the research that led to the discovery and elucidation of this pathway. The goal of the proposed research is to identify key regulatory components of this pathway in order to uncover new targets for pharmaceutical intervention.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM041890-24
Application #
8269028
Study Section
Molecular and Integrative Signal Transduction Study Section (MIST)
Program Officer
Anderson, Vernon
Project Start
1995-04-01
Project End
2013-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
24
Fiscal Year
2012
Total Cost
$523,315
Indirect Cost
$222,559
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Hu, Hai; Juvekar, Ashish; Lyssiotis, Costas A et al. (2016) Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton. Cell 164:433-46
Mayer, Ingrid A; Abramson, Vandana G; Formisano, Luigi et al. (2016) A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clin Cancer Res :
Lien, Evan C; Lyssiotis, Costas A; Cantley, Lewis C (2016) Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer. Recent Results Cancer Res 207:39-72
Wang, Yubao; Begley, Michael; Li, Qing et al. (2016) Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival. Proc Natl Acad Sci U S A 113:9810-5
Juvekar, Ashish; Hu, Hai; Yadegarynia, Sina et al. (2016) Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion. Proc Natl Acad Sci U S A 113:E4338-47
Breitkopf, Susanne B; Yang, Xuemei; Begley, Michael J et al. (2016) A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2. Sci Rep 6:20471
Lien, Evan C; Lyssiotis, Costas A; Juvekar, Ashish et al. (2016) Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer. Nat Cell Biol 18:572-8
Shim, Hyeseok; Wu, Chuan; Ramsamooj, Shivan et al. (2016) Deletion of the gene Pip4k2c, a novel phosphatidylinositol kinase, results in hyperactivation of the immune system. Proc Natl Acad Sci U S A 113:7596-601
Liu, Pengda; Gan, Wenjian; Chin, Y Rebecca et al. (2015) PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex. Cancer Discov 5:1194-209
Dibble, Christian C; Cantley, Lewis C (2015) Regulation of mTORC1 by PI3K signaling. Trends Cell Biol 25:545-55

Showing the most recent 10 out of 143 publications